,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04']
extraordinary scenes at the #asco22 plenary session as destiny-breast04 establishes t-dxd as the new standard of care in her2-low hr+/hr- metastatic #breastcancer standing ovation from attendees and excitement not seen since the launch of adjuvant trastuzumab 
Radiation Oncologist and Clinical Director, wouldbe cyclist, sometimes pianist. Views are my own, RTs not